Menu Back toSession-5-Biosimilars-in-Practice-Critical-Market-Opportunities-Awaiting-to-be-Seized
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Session 5: Biosimilars in Practice – Critical Market Opportunities Awaiting to be Seized
- Head of Global Biosimilars Policy
- Mylan, United States
The US biologic payer and reimbursement framework has presented challenges for a biologic multi-source market, with a number of barriers blocking meaningful utilization and update. This session focuses on identifying mechanisms to overcome market access barriers in the US and build a suitable environment to release the untapped potential of biosimilar medicines competition.
Learning Objective : At the conclusion of this session, participants should be able to:
- Appraise the impact of market barriers on biosimilar use in the US in 2019
- Illustrate, by case studies, the impact on clinical use of biosimilars of common contracting features
- Identify concrete policy solutions which, when implemented, can deliver the most significant improvement in creating a functioning US biosimilars market
US Biosimilar Industry Perspective
Juliana Marguerite Reed, MS
- Vice President, Corporate Affairs, Global I & I and Biosimilars Lead
- Pfizer, Inc., United States
Global Perspective 2030 on Biosimilars
- Senior Vice President and Executive Director
- IQVIA, United States
- Attorney Advisor
- Office of Policy Planning at Federal Trade Commission, United States